An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To compare AS-101 dosing schedules (once a week; 3 times a week; 5 times a week; or 5 times
per week on alternate weeks) on the effect on clinical immunology and virus burden in AIDS or
AIDS related complex (ARC) patients.